Research programme: antibody based therapeutics - Celgene/Sutro Biopharma

Drug Profile

Research programme: antibody based therapeutics - Celgene/Sutro Biopharma

Alternative Names: Anti-BCMA antibody-drug conjugate - Celgene/Sutro; Antibody-drug conjugates - Celgene/Sutro; Bispecific antibody - Celgene/Sutro

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation; Sutro Biopharma
  • Class Antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Multiple myeloma

Most Recent Events

  • 10 Aug 2017 Sutro Biopharma modifies its agreement with Celgene to refocus on 4 preclinical cancer programmes
  • 10 Aug 2017 Preclinical trials in Cancer in USA (Parenteral)
  • 10 Aug 2017 Preclinical trials in Multiple myeloma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top